logo
  

Fennec Pharma Announces Availability Of PEDMARK - Quick Facts

Fennec Pharmaceuticals Inc. (FENC; FRX.TO) announced the U.S. commercial launch and availability of PEDMARK to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. PEDMARK was approved by the U.S. FDA in September 2022. The company also has established Fennec HEARS, a single source program designed to connect PEDMARK patients to both patient financial and product access support.

The company noted that the Marketing Authorization Application for sodium thiosulfate is currently under evaluation by the European Medicines Agency.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
RELATED NEWS
Follow RTT